durvalumab: latest news - GoINPHARMA
Wednesday, 26 September 2018 - 2:08


FDA lifts hold for AstraZeneca’s durvalumab

AstraZeneca will resume the clinical trials for durvalumab, one of the most controversial and relevant anti-cancer immunotherapies being studied, as the US regulatory authority lifted the hold on the enrollment of new patients for clinical trials, imposed last month, following…